These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 9578421)

  • 1. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
    Lethé B; van der Bruggen P; Brasseur F; Boon T
    Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
    Zakut R; Topalian SL; Kawakami Y; Mancini M; Eliyahu S; Rosenberg SA
    Cancer Res; 1993 Jan; 53(1):5-8. PubMed ID: 8416750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
    van der Bruggen P; Szikora JP; Boël P; Wildmann C; Somville M; Sensi M; Boon T
    Eur J Immunol; 1994 Sep; 24(9):2134-40. PubMed ID: 7522162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
    J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
    Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
    Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
    J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
    Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of the MAGE-1 gene expression in hepatocellular carcinoma.
    Yamashita N; Ishibashi H; Hayashida K; Kudo J; Takenaka K; Itoh K; Niho Y
    Hepatology; 1996 Dec; 24(6):1437-40. PubMed ID: 8938177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.
    Gibbs P; Hutchins AM; Dorian KT; Vaughan HA; Davis ID; Silvapulle M; Cebon JS
    Melanoma Res; 2000 Jun; 10(3):259-64. PubMed ID: 10890380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
    Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
    Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
    Zennadi R; Abdel-Wahab Z; Seigler HF; Darrow TL
    Cell Immunol; 2001 Jun; 210(2):96-105. PubMed ID: 11520076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription.
    Labarriere N; Diez E; Pandolfino MC; Viret C; Guilloux Y; Le Guiner S; Fonteneau JF; Dreno B; Jotereau F
    J Immunol; 1997 Feb; 158(3):1238-45. PubMed ID: 9013965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.
    de Vrij J; Uil TG; van den Hengel SK; Cramer SJ; Koppers-Lalic D; Verweij MC; Wiertz EJ; Vellinga J; Willemsen RA; Hoeben RC
    Gene Ther; 2008 Jul; 15(13):978-89. PubMed ID: 18323790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.